2 assets in Respiratory Syncytial Virus Infectious Disease

Therapeutic assets addressing Respiratory Syncytial Virus Infectious Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nirsevimab Respiratory Syncytial Virus Infectious Disease	Menzies School of Health Research	P4	BB (65)
Recombinant Respiratory Syncytial Virus Pre-Fusion F Protein Antigen Respiratory Syncytial Virus Infectious Disease	Medical University of Vienna	P2	CCC (53)